论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Xia LZ, Tan SM, Zhou YJ, Lin JG, Wang HR, Oyang LD, Tian YT, Liu L, Su M, Wang H, Cao D, Liao QJ
Received 29 December 2017
Accepted for publication 9 February 2018
Published 11 April 2018 Volume 2018:11 Pages 2063—2073
DOI https://doi.org/10.2147/OTT.S161109
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 2
Editor who approved publication: Dr Samir Farghaly
Abstract: Cancer is a group of
cells that malignantly grow and proliferate uncontrollably. At present,
treatment modes for cancer mainly comprise surgery, chemotherapy, radiotherapy,
molecularly targeted therapy, gene therapy, and immunotherapy. However, the
curative effects of these treatments have been limited thus far by specific
characteristics of tumors. Abnormal activation of signaling pathways is
involved in tumor pathogenesis and plays critical roles in growth, progression,
and relapse of cancers. Targeted therapies against effectors in oncogenic
signaling have improved the outcomes of cancer patients. NFκB is an important
signaling pathway involved in pathogenesis and treatment of cancers. Excessive
activation of the NFκB-signaling pathway has been documented in various tumor
tissues, and studies on this signaling pathway for targeted cancer therapy have
become a hot topic. In this review, we update current understanding of the
NFκB-signaling pathway in cancer.
Keywords: nuclear factor
kappa-B, p65, signaling pathway, cancer, inflammation
